Custom Recombinant Antibody Production Service

Recombinant antibodies are generated through defined antibody gene sequences expressed in controlled host systems, offering improved reproducibility, sequence traceability, and batch consistency compared with conventional serum- or hybridoma-derived antibodies. Because recombinant production relies on known antibody sequences, researchers can more easily optimize antibody format, engineer functional domains, and reproduce expression across projects and production batches.

At Biocrest Science, we provide flexible recombinant antibody production services for research, assay development, and early-stage therapeutic workflows. Our platform integrates antibody sequencing, vector construction, recombinant expression, purification, and downstream engineering to support a wide range of antibody formats and applications. Services can be configured as full sequence-to-antibody workflows or modular production projects depending on customer requirements.

Recombinant Antibody Production Platforms

Different recombinant expression systems may be selected depending on antibody format, yield requirements, and downstream applications.

Expression System	Antibody Formats Produced	Best For	Key Advantages
Prokaryotic Expression System	VHH, scFv and fusion proteins, humanized single-chain antibodies, etc.	Rapid production of antibody fragments	Fast, low cost
Yeast Expression System	VHH, scFv and fusion proteins, humanized single-chain antibodies, etc.	Medium-to-high yield production of antibody fragments	Balances cost and yield
Mammalian Expression System (including HEK293 transient / CHO / stable cell lines)	VHH, scFv, various species IgG, Fab, humanized antibodies, chimeric antibodies, etc.	Full-length antibodies, complex structures, therapeutic antibodies	Proper folding and glycosylation, scalable

Expression platform selection is determined based on antibody format, structural complexity, and intended downstream use.

Supported Antibody Formats

We support recombinant production and engineering of multiple antibody formats:

Projects may begin from:

• Antibody sequences
• Hybridoma cells
• PBMC/B-cell samples
• Published sequences or customer-provided constructs

Applications & Use Cases

Recombinant antibodies produced through our services are commonly used in:

Application-specific validation is not automatically included for all projects. Validation workflows can be customized based on downstream assay requirements and project goals.

Overview of the Workflow

Phase	Service	Description	Deliverables	Timeline
Phase 1	Full Gene Synthesis & Expression Vector Construction	Target antibody gene is synthesized and cloned into an expression vector	Recombinant expression plasmid	~3–5 days
Phase 2	Transformation	The constructed plasmid is introduced into host cells	Transformed host cells	~2–3 days
Phase 3	Small-Scale Expression & Testing	Transfection into host cells, followed by preliminary expression and validation of the target antibody	Small-scale expression data	~5–7 days
Phase 4	Scale-Up Culture & Purification	Large-scale culture and purification using affinity resin systems	Purified recombinant antibody	~7–10 days

Typical total timeline: ~2–3 weeks
Timelines may vary depending on antibody format, expression system, purification requirements, and downstream validation scope.

Expression & Engineering Options

Additional engineering and optimization services are available following recombinant antibody production:

Expression workflows can be optimized for research-use antibodies, translational studies, or early therapeutic development projects.

Quality & Validation

We implement quality control and analytical workflows appropriate for recombinant antibody production.

Standard Quality Control
Sequence verification, Purity assessment (SDS-PAGE), Concentration determination

Functional Validation (performed upon request)
ELISA binding analysis, Flow cytometry validation, Comparative antigen-binding studies, Application-specific testing

Optional Characterization
Affinity measurement (SPR or BLI), SEC-HPLC aggregation analysis, Endotoxin testing

Validation scope is determined during project planning and adjusted based on research objectives.

Why Researchers Choose Biocrest Science

• Flexible recombinant expression systems – HEK293, CHO, and bacterial platforms available for different antibody formats
• Integrated sequence-to-antibody workflow – From gene synthesis to purified recombinant antibody production
• Support for diverse antibody formats – Conventional IgG, scFv, Fab, VHH, Fc-fusion, and engineered antibodies
• Scientist-led workflow optimization – Customized strategies based on target biology and application requirements
• Expandable downstream engineering capabilities – Support for humanization, affinity optimization, and advanced antibody engineering

Because recombinant antibody performance may vary depending on sequence properties, expression conditions, and structural complexity, production outcomes can differ between projects. Our team works to optimize each stage while maintaining realistic expectations regarding yield, purity, and functional activity.

Start Your Project

Whether you require recombinant antibodies for assay development, functional studies, or therapeutic research, our team can help design a workflow aligned with your project goals.

• Submit antibody sequences or project details for evaluation
• Consult with our scientists on expression platform selection
• Request a quote based on antibody format and production scale